News

The latest from Orpyx

Dr. Breanne Everett selected as one of six inaugural winners

Calgary, AB, Canada, April 28, 2016 - Orpyx Medical Technologies Inc. (“Orpyx”) is proud to announce its CEO and Co-Founder, Dr. Breanne Everett was named one of the six national winners of the inaugural Governor General’s Innovation Award in Canada.

The goal of the Governor General’s Innovation Award is to inspire Canadians to embrace innovation and to emulate innovative, entrepreneurial risk-takers who have developed new or groundbreaking ways of creating value and a meaningful impact on our quality of life.

“I am thrilled and honoured to receive the Governor General’s Innovation Award.” said Dr. Breanne Everett, CEO and Co-Founder, Orpyx. “Recognition like this is important in nurturing Canada’s innovation economy and I hope my efforts, and those of my team, can inspire others to do the same.”

The Governor General’s Innovation Awards recognize and celebrate outstanding Canadian individuals, teams, and organizations — trailblazers and creators whose innovations are exceptional and inspiring to the future of the next generation.

About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

About the Governor General’s Innovation Award
The Governor General’s Innovation Awards is to inspire Canadians to embrace innovation and to emulate innovative, entrepreneurial risk-takers who have developed new or better ways of creating value and who are having a meaningful impact on our quality of life. As innovation and an entrepreneurial spirit are fundamentally important to all Canadians and can have a transformative, positive impact—regardless of whether it is in the private, public or not-for-profit realms—the awards encompass all sectors of Canadian society.

Each year, up to six award winners will be identified through a two-stage, merit-based selection process. This process is managed by the Canada Foundation for Innovation. The program operates on an annual cycle, with an awards ceremony held each spring. The Governor General’s Innovation Awards Advisory Committee, made up of highly accomplished Canadians from all sectors, provides oversight and strategic direction for the program. The Office of the Secretary to the Governor General oversees the execution of all aspects of the program.

To learn more about the Governor General’s Innovation Award and this year’s winners, please visit: www.innovation.gg.ca

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

Orpyx's SurroSense Rx™ was recently mentioned LER Magazine. Lower Extremity Review or LER Magazine fills the lower extremity information gap for practitioners in the fields of Podiatry, Physical Therapy, O&P Pedorthics, and Orthopaedics. The article discusses how athletes have been quick to embrace smart insoles and the biomechanical data generated by the devices’ embedded sensors. However, experts believe smart insoles may also have potential clinical applications for patients with foot health problems, such as diabetic neuropathy.

Surrosense Rx is a sensor-embedded insert that captures pressure data from feet. The data are sent wirelessly to a smart watch device (which is packaged with the insoles). According to the company, the “smart watch alerts you when dangerous time and pressure levels are detected, so you can modify behavior and avoid damage.”

The market for Surrosense Rx is patients with diabetes. Bijan Najafi, PhD, director of clinical research in the Division of Vascular Surgery and Endovascular Therapy at Baylor College of Medicine in Houston, and colleagues recently conducted a pilot study to test the recurrence of diabetic foot ulcers in patients using the device, which is considered a class I medical device and therefore is exempt from FDA 510(k) premarket review.

The study included 21 patients with diabetic neuropathy and recently healed ulcers. The participants received an average of 3.38 daily alerts per day, of which nearly 44% were successfully managed, Najafi said. In addition, the majority of the alerts (45.8%) were related to pressure changes under the metatarsal heads, which is one of the plantar surfaces that is most prone to ulceration.

Real-time feedback and a “user-friendly” interface are two factors that can make a smart insole stand out, said Najafi, who is also director of Interdisciplinary Consortium on Advanced Motion Performance (iCAMP) at the University of Arizona, where the pilot study was conducted. The study was partially funded by Orpyx.

“The big challenge is still how to visualize or feed back key information to patients for assisting them to take care of their own health,” Najafi said. “Another key challenge is how to engage patients to continue wearing these insoles.”

For Armstrong, a coauthor on the study, smart insoles like Surrosense Rx that rely on sensory substitution technology—or the use of one sensory modality to supply environmental information normally gathered by another sense while still preserving some of the key functions of the original sense—will have the longest staying power in the market.

“There are other kinds of insoles that measure pressure or temperature, but most of them haven’t reached the same level of sophistication as the sensory substitution devices,” he said.

Read the full article here.

Assessing The Potential Of Insoles And Sensory Substitution For Patients With Diabetes

Orpyx's SurroGait Rx™ was recently mentioned in Volume 29 - Issue 3 - March 2016 of Podiatry TodayPodiatry Today is an award-winning, premier publication that emphasizes informative clinical features and columns as well as practice management articles. The authors Dr. Breanne Everett - Orpyx's CEO and Co-Founder, Dr. Asmussen, and Dr. Armstrong discuss changing perspectives on neuroplasticity and the evolution of sensory substitution, and how these trends have led to wearable technology with potential benefits in this high-risk population. 

The SurroGait Rx™ Sensory Substitution System may improve gait and balance in individuals with reduced or absent plantar pressure sensation. With lost sensation in the feet, it becomes difficult to detect changes in posture. This ultimately impacts a person’s ability to stand or walk. SurroGait Rx technology effectively replaces the lost or impaired plantar pressure proprioception with a new type of sensory input.

The SurroGait Rx was designed to help people with impaired foot sensation to be aware of their base of support limits. The SurroGait Rx functions by placing pressure sensing insoles in the shoes of patients to detect when they are approaching the limits of their base of support. Similar to how the “rumble strips” inform people about where they are in their own lane while driving, the SurroGait Rx uses information from the pressure sensing insoles to tell people about their base of support via vibrations from a vest worn on the back.

Research has shown that the SurroGait Rx has beneficial effects on gait and posture control in individuals with peripheral neuropathy. In a small scale clinical trial, researchers sought to determine if there were changes in measures of gait and balance control after patients used the SurroGait Rx device for an extended period of time. Specifically, researchers obtained baseline gait and balance control measures from 10 patients with peripheral neuropathy before wearing the SurroGait Rx device for four weeks. These baseline measures included 1) center of pressure path length to assess balance, 2) spatial/temporal stride and step characteristics to determine gait kinematic differences and 3) kinetic variable of gait.

In terms of balance control, patients with peripheral neuropathy showed less sway when balancing with their eyes closed, suggesting improved balance control. These changes occurred because of the demand to incorporate somatosensory input to guide balance control in the absence of vision. Given that patients with peripheral neuropathy already have compromised plantar pressure proprioception, they likely relied on the vibrotactile inputs from the SurroGait Rx device to improve their perception of their swaying body and accordingly improved their balance.

In terms of gait measures, the SurroGait Rx device also shows beneficial effects. When wearing the device, patients with peripheral neuropathy had increased stride frequency (i.e., more steps taken over a fixed distance) and  reduced variability of stride frequency (i.e., keeping the number of steps taken over a fixed distance consistent). Overall, the evidence suggests there is a positive benefit of the SurroGait Rx for patients with peripheral neuropathy in the form of immediate improvements in gait and balance.

Outside of direct sensory substitution-based feedback, there is also a role to play for cue-based feedback to patients with diabetic peripheral neuropathy. Another technology, the SurroSense Rx™ smart insole system does this by providing offloading and activity guidance based on data collected in a pressure sensitive insole. While the product’s impact with respect to gait and balance is less pronounced, the simplicity of the system - with its inconspicuousness and potential ease of deployment - provides a high degree of promise in its own right.

Read the full article here.

Calgary, AB, Canada, January 26, 2016 - Orpyx Medical Technologies Inc. announced today that the New Zealand intellectual property office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx (TM) product and future products, such as SurroGait Rx (TM), in New Zealand.

“We are very pleased to see the first of our innovations recognized by the New Zealand intellectual property office,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc. “Orpyx has made, and continues to make, substantial investment in our intellectual property base, as we lead the world in the development of sensor-based wearable technologies for medical applications.”

SurroSense Rx is designed to actively prevent the complications associated with peripheral neuropathy. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via a smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behavior can be proactively changed and devastating complications avoided.

About Orpyx Medical Technologies Inc.
Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot sores-or ulcers-which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

Clinical study to begin in 2016

Calgary, AB, Canada, January 11, 2016 - Orpyx Medical Technologies Inc. today announced a clinical trial agreement with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School in Boston, USA. The study will use the Orpyx LogR plantar pressure research system to measure gait and balance parameters in a variety of patients with cardiac and vascular disorders in an attempt to correlate global musculoskeletal changes (as represented by balance/foot pressure physiology) to discrete subsets of cardiovascular disease.

The Orpyx LogR is a solution designed for the accurate, efficient, and real-time measurement of foot and plantar pressure analysis. Comprised of sensor embedded inserts, iOS application and cloud based software for data storage and management, this system is used by researchers to assess foot and ankle health and performance for a variety of different applications including: gait and balance assessments, posture research, rehabilitation, footwear and orthotic design, sport biomechanics, injury prevention, and fall prevention.

“We look forward to testing the role of both gait and balance in the stratification of patients with cardiovascular disease in order to better understand the quality and usability of an integrated foot pressure measurement system as a tool in precision medicine,” said Calum MacRae, MD, PhD, chief, Cardiovascular Medicine at Brigham and Women’s Hospital. “Our goal is to determine if there is a skeletal muscle signature that defines patients with increased perioperative risk or with specific subsets of vascular disease or heart failure.”
“We are very excited about Brigham and Women’s Hospital decision to use the Orpyx LogR in this study. Their reputation and history of innovation provides a unique opportunity to extend the utility of our novel technology and provide continued demonstration of the broader application of our platform in increasingly diverse clinical settings,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc.
About Orpyx Medical Technologies Inc.
Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot sores-or ulcers-which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

Orpyx Welcomes New Director

November 15, 2015

News  

David Taylor Brings his Wealth of Experience to the Board

Calgary, AB, Canada, November 15, 2015 - Orpyx Medical Technologies Inc. announced today that David Taylor has joined its Board of Directors, effective immediately. Mr. Taylor is the President of Resman Holdings Ltd., an investment firm with a diverse portfolio of investments across industries. 

“David brings broad and deep business experience from multiple industries that will add a valuable perspective to Orpyx as we grow,” said Dr. Breanne Everett, Founder and CEO. “We are proud to welcome him as a director and I look forward to start working with him.”

In addition to his role at Resman Holdings Ltd., Mr. Taylor’s is concurrently the President of several other businesses, including, Engineered Air, The Glenmore Inn and Convention Center, Airstate Ltd., Thunderstone Quarries Canmore Ltd., and Three Sisters Mountain Village Properties. He also serves on the boards of Sabell Corporation, Stewart Creek Golf Course, Pureleau Industries Inc., Curve Dental, and Edon Management. Mr. Taylor is also active in the community as a member of the Schulich Advisory Council at the University of Calgary School of Engineering, and Chair of BOWDA (Bow Valley Builders and Developers Association).

"I am elated to join the Orpyx Board," said David Taylor. "The team here is delivering life-changing products to patients who really need them and it is a special opportunity to be a part of it."
For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

The Discovery Channel’s Daily Planet Reviews Orpyx’s LogR System

CALGARY, AB October 27, 2015The LogR from Orpyx Medical Technologies Inc. (“Orpyx”) was featured on The Discovery Channel’s hit television series, Daily Planet. The LogR system is a mobile kit targeted for research-focused plantar pressure measurement – collecting data in real time, in the real world. Samuel Blades, PhD candidate from the University of Victoria’s Department of Exercise was approached by the television station to record a segment on his applied sports science research. As described in the segment, the progress made to date is nothing short of “revolutionary”.

Alongside Canadian top athlete Hillary Stellingwerff, Blades discussed the importance of runners to assess how the foot is interacting with the ground underneath them, analyze the patterns and unveil areas of the foot that may pose a certain risk. Most athletes do not run on the fancy treadmills that can be found in a lab setting; they are outdoors, which is where Orpyx’s LogR system provides a superior measurement system.

The LogR is a tool to accurately and efficiently measure foot pressures for analysis. Comprised of sensor embedded inserts, real-time iOs application and cloud based software for data storage and management, this system is crucial to assess overall foot and ankle health for a myriad of different applications including: gait and balance assessments, posture research, rehabilitation, footwear and orthotic, design, sport biomechanics, injury prevention, fall prevention and more.

The work done to date would not be possible without the partnership of Mitacs, Own the Podium, the University of Victoria, Canadian Sport Institute Pacific and Orpyx to provide a new opportunity for applied sport science research.  To watch the segment, click here

On November 12, 2013 the Ward of the 21st Century ("W21C") hosted its first Innovation Academy.  In partnership with an international network, this event focused on identifying and nurturing health innovations that will contribute to the improvement of health service safety and quality of care both now and in the future.

W21C followed up with Orpyx to get an update on their progress over the past year.  Watch the update here.

Orpyx Gives Online Visitors A Warmer Welcome

CALGARY, AB August 13, 2015 – Orpyx Medical Technologies Inc. (“Orpyx”) is pleased to announce the launch of its fully revamped website: www.orpyx.com. The website has been redesigned with our customer needs in mind. We’ve focused on making the site easier to navigate, more impactful and providing greater support resources.

A big part of our mission is to make wearable health technologies available and accessible to the people who need them the most – the patients. The Orpyx website assists patients with peripheral neuropathy, their families and their providers in making well-informed decisions regarding their care plans. The website features Orpyx’s flagship product, the SurroSense Rx™ system, which is a tool to help actively prevent the complications relating to peripheral neuropathy, aid in the healing of existing complications and track progress.

Of course, the launch of our redesigned website is just the beginning. We will be continuing to improve the content, features and resources in the near and distant future.

ABOUT ORPYX MEDICAL TECHNOLOGIES:

Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the health care system over $14 billion annually.

 The SurroSense Rx system is a tool to help actively prevent the complications associated with peripheral neuropathy, aid in the healing of existing complications and track progress. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behaviour can be proactively changed and devastating complications avoided.

 In addition to the benefits of having real-time feedback, the system also tracks compliance and performance metrics over time so that the patient and primary care team can monitor progress and adjust care recommendations accordingly.

Orpyx was recently mentioned in the July 2015 edition of the Lower Extremity Review.  At the International Working Group on the Diabetic Foot in the Netherlands, pressure offloading was a hot topic.  Lower Extremity Review author, Cary Groner, provides a synopsis of the conference and what clinicians are suggestion for best practice recommendations on offloading.  They also discuss Orpyx's smart insoles!  Read the full article here.

1 2 3 4 Next »